Treatment of invasive aspergillosis: Polyenes, echinocandins, or azoles?

Medical Mycology

Volumn 44, Issue SUPPL. 1, 2006, Pages 357-362

  Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aspergillosis; Echinocandins; Extended spectrum azoles; Polyenes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLODEXTRIN; CYCLOSPORIN; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; EARLY INTERVENTION; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION RISK; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; RISK BENEFIT ANALYSIS; SKIN TOXICITY; SURVIVAL RATE; TREATMENT OUTCOME; VISUAL DISORDER;

ASPERGILLUS;

EID: 33749523568     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780600826715     Document Type: Article

References (48)

1. Lin, SJ and Schranz, J and Teutsch, SM. (2001) Aspergillosis case - Fatality rate: Systematic review of the literature Clin Infect Dis, 32, pp. 358-366.
2. Patterson, TF and Kirkpatrick, WR and White, M and (2000) Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group Medicine (Baltimore), 79, pp. 250-260.
3. Ostrosky-Zeichner, L and Marr, KA and Rex, JH and (2003) Amphotericin B: time for a new 'gold standard' Clin Infect Dis, 37, pp. 415-425.
4. Patterson, TF and Boucher, HW and Herbrecht, R and (2005) Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome Clin Infect Dis, 41, pp. 1448-1452.
5. Patterson, TF. (2005) Advances and challenges in the management of invasive mycoses Lancet, 366, pp. 1013-1025.
6. Wingard, JR and Kubilis, P and Lee, L and (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis Clin Infect Dis, 29, pp. 1402-1407.
7. Bates, DW and Su, L and Yu, DT and (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy Clin Infect Dis, 32, pp. 686-693.
8. Steinbach, WJ and Benjamin, DK, Jr and Kontoyiannis, DP and (2004) Infections due to Aspergillus terreus: A multicenter retrospective analysis of 83 cases Clin Infect Dis, 39, pp. 192-198.
9. SuttonDA, FothergillAW, RinaldiMG. Aspergillusin vitro antifungal susceptibility data: New millennium trends (abstract 16). In: Abstracts of Advances Against Aspergillosis, San Francisco, CA, 9-11 September 2004. 2004 p 60.
10. Walsh, TJ and Finberg, RW and Arndt, C and (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia N Engl J Med, 340, pp. 764-771.
11. Walsh, TJ and Goodman, JL and Pappas, P and (2001) Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study Antimicrob Agents Chemother, 45, pp. 3487-3496.
12. Walsh, TJ and Teppler, H and Donowitz, GR and (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med, 351, pp. 1391-1402.
13. Bowden, R and Chandrasekar, P and White, MH and (2002) A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients Clin Infect Dis, 35, pp. 359-366.
14. Ellis, M and Spence, D and de Pauw, B and (1998) An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis Clin Infect Dis, 27, pp. 1406-1412.
15. Linden, PK and Coley, K and Fontes, P and (2003) Invasive aspergillosis in liver transplant recipients: Outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B Clin Infect Dis, 37, pp. 17-25.
16. Barrett, JP and Vardulaki, KA and Conlon, C and (2003) A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations Clin Ther, 25, pp. 1295-1320.
17. Cornely, OA and Maertens, J and Bresnik, M and (2005) Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial) Blood (ASH Annual Meeting Abstracts), 106, pp. 3222.
18. Imhof, A and Walter, RB and Schaffner, A. (2003) Continuous infusion of escalated doses of amphotericin B deoxycholate: An open-label observational study Clin Infect Dis, 36, pp. 943-951.
19. Andes, D and Stamsted, T and Conklin, R. (2001) Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model Antimicrob Agents Chemother, 45, pp. 922-926.
20. Denning, DW. (2003) Echinocandin antifungal drugs Lancet, 362, pp. 1142-1151.
21. Bowman, JC and Hicks, PS and Kurtz, MB and (2002) The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro Antimicrob Agents Chemother, 46, pp. 3001-3012.
22. Maertens, J and Raad, I and Petrikkos, G and (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis, 39, pp. 1563-1571.
23. Perea, S and Gonzalez, G and Fothergill, AW and (2002) In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp Antimicrob Agents Chemother, 46, pp. 3039-3041.
24. Petraitis, V and Petraitiene, R and Sarafandi, AA and (2003) Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin J Infect Dis, 187, pp. 1834-1843.
25. Kirkpatrick, WR and Perea, S and Coco, BJ and (2002) Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis Antimicrob Agents Chemother, 46, pp. 2564-2568.
26. Aliff, TB and Maslak, PG and Jurcic, JG and (2003) Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin Cancer, 97, pp. 1025-1032.
27. Kontoyiannis, DP and Hachem, R and Lewis, RE and (2003) Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies Cancer, 98, pp. 292-299.
28. Steinbach, WJ and Stevens, DA and Denning, DW. (2003) Combination and sequential antifungal therapy for invasive aspergillosis: Review of published in vitro and in vivo interactions and 6281 clinical cases from to 2001 Clin Infect Dis, 37(Suppl 3), pp. S188-S224.
29. Marr, KA and Boeckh, M and Carter, RA and (2004) Combination antifungal therapy for invasive aspergillosis Clin Infect Dis, 39, pp. 797-802.
30. Marr, KA and Crippa, F and Leisenring, W and (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants Blood, 103, pp. 1527-1533.
31. Pfaller, MA and Messer, SA and Hollis, RJ and (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000 Antimicrob Agents Chemother, 46, pp. 1032-1037.
32. Herbrecht, R and Denning, DW and Patterson, TF and (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med, 347(6), pp. 408-15.
33. Steinbach, WJ and Stevens, DA. (2003) Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis Clin Infect Dis, 37(Suppl 3), pp. S157-S187.
34. Denning, DW and Ribaud, P and Milpied, N and (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis, 34, pp. 563-571.
35. Schwartz, S and Ruhnke, M and Ribaud, P and (2005) Improved outcome in central nervous system aspergillosis, using voriconazole treatment Blood, 106, pp. 2641-2645.
36. Kauffman, CA. (2004) Zygomycosis: Reemergence of an old pathogen Clin Infect Dis, 39, pp. 588-590.
37. Smith, J and Safdar, N and Knasinski, V and (2006) Voriconazole therapeutic drug monitoring Antimicrob Agents Chemother, 50, pp. 1570-1572.
38. RaadI, ChapmanS, BradsherR, Posaconazole (POS) salvage therapy for invasvie fungal infections (IFI) (abstract M-699). In: Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 30 October-2 November 2004. WashingtonDC: American Society for Microbiology, 2004. p 412.
39. UllmannAJ, LiptonJH, VesoleDH, Posaconazole (POS) vs fluconazole (FLU) for prophylaxis of invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host-disease (GVHD): Results of a multicenter trial (abstract M-716). In: Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2005, WashingtonDC: American Society for Microbiology, 2005: 39.
40. CornelyOA, MaertensJ, WinstonDJ, Posaconazole (POS) vs. standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): Impact on mortality (abstract M-722b). In: Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December, 2005. WashingtonDC: American Society for Microbiology, 2005: 207.
41. Maertens, J and Theunissen, K and Verhoef, G and (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study Clin Infect Dis, 41, pp. 1242-1250.
42. Donnelly, JP. (2006) Polymerase chain reaction for diagnosing invasive aspergillosis: Getting closer but still ways to go Clin Infect Dis, 42, pp. 487-489.
43. Marr, KA and Balajee, SA and McLaughlin, L and (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance J Infect Dis, 190, pp. 641-649.
44. Odabasi, Z and Mattiuzzi, G and Estey, E and (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome Clin Infect Dis, 39, pp. 199-205.
45. White, PL and Linton, CJ and Perry, MD and (2006) The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting Clin Infect Dis, 42, pp. 479-486.
46. Wingard, JR and White, MH and Anaissie, E and (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia Clin Infect Dis, 31, pp. 1155-1163.
47. Leenders, ACAP and Daenen, S and Jansen, RLH and (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections Brit J Haematol, 103, pp. 205-212.
48. Caillot, D and Bassaris, H and McGeer, A and (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS Clin Infect Dis, 33(8), pp. E83-E90.